Induction Therapy for Locally Advanced, Resectable Cancer of the Esophagus, GE Junction and Gastric Cancer: A Phase I Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery (IRUSZACT0064).

Trial Profile

Induction Therapy for Locally Advanced, Resectable Cancer of the Esophagus, GE Junction and Gastric Cancer: A Phase I Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery (IRUSZACT0064).

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Vandetanib (Primary) ; Carboplatin; Fluorouracil; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2017 Status changed from recruiting to completed, based on the results published in the American Journal of Clinical Oncology.
    • 01 Aug 2017 Results published in the American Journal of Clinical Oncology.
    • 03 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top